Meeting
2023 ASCO Annual Meeting
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
Authors
Tian Zhang
University of Texas Southwestern Medical Center, Dallas, TX
Tian Zhang , Lauren Howard , Bridget F. Koontz , Scott T. Tagawa , Himanshu Nagar , Rhonda L. Bitting , Bart Frizzell , Luke T. Nordquist , Julia Rasmussen , Carolyn Winters , Colleen Riggan , Marco Reyes-Martinez , Catrin Davies , Steven Gray , Carly Newman , Escarleth Fernandez , Michael Roger Harrison , Daniel J. George , Yuan Wu , Andrew J. Armstrong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT03311555
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5016)
DOI
10.1200/JCO.2023.41.16_suppl.5016
Abstract #
5016
Poster Bd #
110
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2019 ASCO Annual Meeting
A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).
First Author: Tian Zhang
Poster
2020 ASCO Virtual Scientific Program
RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
First Author: Edwin Melencio Posadas
Poster
2019 Genitourinary Cancers Symposium
Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.
First Author: Andrew J. Armstrong